Last reviewed · How we verify
BR1400-C
BR1400-C is a small molecule that targets the renin-angiotensin system.
BR1400-C is a small molecule that targets the renin-angiotensin system. Used for Hypertension.
At a glance
| Generic name | BR1400-C |
|---|---|
| Also known as | Placebo |
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Drug class | Renin-angiotensin system inhibitor |
| Target | ACE2 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
BR1400-C works by inhibiting the angiotensin-converting enzyme 2 (ACE2), which plays a crucial role in the renin-angiotensin system. This inhibition leads to a decrease in angiotensin II levels, resulting in vasodilation and reduced blood pressure.
Approved indications
- Hypertension
Common side effects
- Headache
- Dizziness
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BR1400-C CI brief — competitive landscape report
- BR1400-C updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI